Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
1696000 participants
INTERVENTIONAL
2025-11-01
2027-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
We plan to conduct STROKE 120 ACTION, a national cluster randomized controlled trial, to determine whether implementing a STROKE 120 multifaceted intervention campaign can reduce pre-hospital delay in AIS, increase the 4.5-hour hospital arrival rate, and improve survival, disability, and healthcare costs. The STROKE 120 ACTION trial will recruit 16 community units across 8 regions in China, with each region enrolling 2 community units with a residential population of at least 110,000 and comparable demographic characteristics. To avoid cross-contamination, the participating community clusters will maintain a physical distance of more than 20 kilometers. Within each region, the 2 community units will be randomly assigned at a 1:1 ratio to receive the intervention (12-month usual health policy plus STROKE 120 multifaceted intervention campaign; 3-month intensive period and 9-month maintenance period) or control (12-month usual health policy alone). The study outcomes and related data on incident AIS cases within each participating community unit will be collected after the implementation of STROKE 120 multifaceted intervention campaign (from month 1 to month 12 of multifaceted intervention campaign). The primary outcome is proportion of hospital arrival within 4.5 hours after symptom onset within participating community units. Secondary outcomes include time from onset to hospital admission, time from onset to action, use of 120 emergency ambulances, IVT, MT, total hospitalization costs, out-of-pocket costs, composite outcome of death or major disability (modified Rankin scale score \[mRS\] ≥3) at 3 months, ordinal 7-level mRS score at 3 months, all-cause mortality within 3 months. The sample size was calculated according to the following estimates: (1) a significance level of 0.05 for a 2-sided test; (2) statistical power of 85%; (3) 4.5-hour hospital arrival rate of 10% for AIS patients in control group; (4) 4.5-hour hospital arrival rate of 20% among AIS patients in intervention group; (5) intra-class correlation coefficient of 0.03; and (6) a 10% loss to follow-up. The estimated sample size is 3,312 incident AIS patients from 16 community units with an average cluster size of 207 patients per community unit. The annual incidence of AIS is 195 per 100,000 people, and the sample size of participants in each community unit will be 106,000. Thus, the total sample size of the present study will be 1,696,000 participants from 16 community units.
The STROKE 120 ACTION trial will address the critical issue of long pre-hospital delay in AIS in China, and provide profound implications for global stroke prevention and control strategies.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Intensive Care Bundle with Mortality Reduction in Acute Ischemic Stroke Trial
NCT06628817
Intravenous Thrombolytic Therapy for Acute Ischemic Stroke Patients with Low NIHSS and Non-disabling Deficits
NCT06115070
Temporal Trends of Thrombolysis Treatment in Chinese Acute Ischemic Stroke (AIS) Patients From 2007-2017: Analysis of China National Stroke Registry (CNSR) I, II, and III; CTP-Draft Review Performed;
NCT04290494
INtravenous TNK for Acute isChemicsTroke in China
NCT04588337
The Effect of Ginkgolide on Clinical Improvement of Patients With Acute Ischemic Stroke
NCT05663307
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intervention group
Usual health policy plus STROKE 120 multifaceted intervention campaign
STROKE 120 multifaceted intervention campaign
Based on the existing usual health policy, the intervention group will implement a STROKE 120 multifaceted intervention campaign in the intervention community units for a continuous period of 12 months (3-month intensive period and 9-month maintenance period).
The detailed implementation plan for the STROKE 120 multifaceted intervention campaign in the intervention group is as follows:
1. Training medical workers in stroke center;
2. Training emergency center staff and primary care physicians;
3. Conducting public education;
Control group
Usual health policy alone
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
STROKE 120 multifaceted intervention campaign
Based on the existing usual health policy, the intervention group will implement a STROKE 120 multifaceted intervention campaign in the intervention community units for a continuous period of 12 months (3-month intensive period and 9-month maintenance period).
The detailed implementation plan for the STROKE 120 multifaceted intervention campaign in the intervention group is as follows:
1. Training medical workers in stroke center;
2. Training emergency center staff and primary care physicians;
3. Conducting public education;
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. The 2 participating community units in each region should each have a permanent population over 110,000 (people aged 60 years and above accounting for at least 15%), have similar demographic characteristics (e.g., age, gender, and education level), and have comparable local health policies (e.g., medical insurance policies, emergency system framework, stroke emergency map release, and stroke center quality control), economic levels, and public ability to recognize AIS.
2. The participating hospitals in each community unit serve \>90% of AIS patients within the community unit, have a well-established stroke center, and have comparable standardized treatment capabilities for AIS (including 4.5-hour hospital arrival rate of AIS, rate of using 120 emergency ambulances after AIS, and rate of IVT after AIS).
3. The participating communities are capable of implementing STROKE 120 multifaceted intervention campaign within its community unit.
4. To avoid cross-contamination, the physical distance between any two community units exceeds 20 kilometers.
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shanghai Minhang Central Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jing Zhao
Chief of the Department of Neurology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Shanghai Minhang Central Hospital
Shanghai, , China
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2025-055-01K
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.